Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OK-101
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : OKYO Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.
Brand Name : OK-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2022
Lead Product(s) : OK-101
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : OKYO Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Recipient : Amytrx Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.
Brand Name : AMTX-100
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : AMTX-100
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Recipient : Amytrx Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 12, 2022
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Adalvo
Deal Size : Not Applicable
Deal Type : Not Applicable
Adalvo Announces Successful DCP Closure for Icatibant
Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.
Brand Name : Icatibant Acetate-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 28, 2021
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Adalvo
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Thrixopelma pruriens venom peptide
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : University of California
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 20, 2021
Lead Product(s) : Thrixopelma pruriens venom peptide
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : University of California
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Corticotropin
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.
Brand Name : Acthar
Molecule Type : Peptide
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : Corticotropin
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : Adalvo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product
Details : The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : Adalvo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?